Resources

Good Pharmacovigilance Practices (GVP) are a set of measures put into practice in 2012 to facilitate the performance of pharmacovigilance in the European Union (EU). GVP is broken out into several modules that govern different aspects of pharmacovigilance processes.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolytic disease characterized by complement-mediated hemolysis, thrombophilia, bone marrow failure (BMF), and renal disease.

The University of New Mexico’s (UNM) Health Sciences Center (HSC) and Clinical & Translational Science Center (CTSC) supports high quality collaborative translational science locally, regionally, and nationally.

East Lancashire Hospitals NHS Trust (ELHT) is a large, integrated healthcare organization providing high quality acute secondary healthcare for more than 700,000 people of East Lancashire and Blackburn annually.

This article describes a scalable, performant, sustainable global network of electronic health record data for biomedical and clinical research.

Paroxysmal nocturnal hemoglobinuria (PNH), a rare acquired hematologic disorder, can be treated with C5 inhibitors (C5i) such as eculizumab or ravulizumab.

COVID-19 caused or exacerbated negative health outcomes for many people, especially for those with pre-existing comorbidities. Sickle cell disease (SCD) is a rare genetic condition that primarily occurs among African Americans in the United States.

The MetroHealth System, Cuyahoga County’s public health system, provides care to more than 300,000 patients through nearly 1.5 million visits a year at its four hospitals, and more than 20 health centers throughout the county, which includes Cleveland and surrounding suburbs

As the COVID-19 pandemic raged, the healthcare industry was rightfully focused on treating the devastating acute symptoms of the disease.

Penn State College of Medicine is a national leader in pursuing basic, clinical, translational and health services research. Penn State is ranked in the top one percent of the world’s universities, and the College of Medicine boasts a portfolio of nearly $100 million in funded research.

The University of Texas Medical Branch (UTMB) Health’s Blocker Burn Center in Galveston, Texas is nationally and internationally recognized for specialization in the treatment of thermal, chemical and radiation burns.